<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03449147</url>
  </required_header>
  <id_info>
    <org_study_id>7264-030</org_study_id>
    <secondary_id>MK-7264-030</secondary_id>
    <secondary_id>2017-003559-49</secondary_id>
    <nct_id>NCT03449147</nct_id>
  </id_info>
  <brief_title>A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-030)</brief_title>
  <official_title>A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-Month Study to Evaluate the Efficacy and Safety of MK-7264 in Adult Participants With Chronic Cough (PN030)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study will be to evaluate the efficacy of gefapixant (MK-7264)
      in reducing cough frequency as measured over a 24-hour period. It is hypothesized that at
      least one dose of gefapixant is superior to placebo in reducing coughs per hour (over 24
      hours).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will have a main 24-week treatment period and a 28-week extension period of
      treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 15, 2018</start_date>
  <completion_date type="Anticipated">January 4, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 19, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants with refractory or unexplained chronic cough will be randomized to 1 of 3 treatment groups: gefapixant 45 mg twice daily (BID), gefapixant 15 mg BID, or placebo.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>24-hour Coughs per Hour at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>Assessment of 24-hour coughs per hour (average hourly cough frequency based on 24-hour sound recordings), to be evaluated using a digital recording device which records sounds from the lungs and trachea through a chest contact sensor, as well as ambient sounds through a lapel microphone.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Experiencing At Least One Adverse Event (AE) During Treatment and Follow-up</measure>
    <time_frame>Up to 54 weeks</time_frame>
    <description>Assessment of participants who have at least one AE during the main study period (24 weeks), the treatment extension period (28 weeks), and during 2 weeks of follow-up by telephone.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Have a Study Drug Discontinued Due to an AE</measure>
    <time_frame>Up 52 weeks</time_frame>
    <description>Assessment of participants who stop study treatment due to an AE during the main study period (24 weeks) or the treatment extension period (28 weeks).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline of Awake Coughs Per Hour at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>To evaluate the efficacy of gefapixant by assessment of coughs per hour while the participant is awake, evaluated using a chest contact sensor to record sounds from the lungs and trachea and a lapel microphone to record ambient sounds.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a ≥1.3-point Increase from Baseline in the Leicester Questionnaire (LCQ) Total Score at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>To evaluate the ability of gefapixant to provide a clinically significant improvement in cough-specific health related quality of life (HRQoL), as indicated by a ≥1.3-point increase from Baseline in the LCQ total score at Week 24. The 19-item LCQ assesses the impact of cough severity in three HRQoL domains (physical, social and psychological). The LCQ is calculated as a mean score for each domain ranging from 1 to 7, with a total score ranging from 3 to 21.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a ≥30% Reduction From Baseline in 24-hour Coughs Per Hour at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>To evaluate the efficacy of gefapixant based on clinically meaningful (≥30%) reduction from Baseline in 24-hour coughs per hour at Week 24. Coughs per hour are evaluated using a chest contact sensor to record sounds from the lungs and trachea and a lapel microphone to record ambient sounds.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with ≥1.3-point Reduction of Mean Weekly Cough Severity Diary (CSD) Total Score at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>To evaluate the efficacy of gefapixant based on the percentage of participants with ≥1.3-point reduction of the mean weekly CSD total score at Week 24. Participants will record their cough frequency, intensity, and disruption due to cough using the 7-item CSD. Participants will rate each item using an 11-point scale ranging from 0 to 10 with higher scores indicating greater severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with ≥2.7-point Reduction of Mean Weekly CSD Total Score at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>To evaluate the efficacy of gefapixant based on the percentage of participants with ≥2.7-point reduction of the mean weekly CSD total score at Week 24. Participants will record their cough frequency, intensity, and disruption due to cough using the 7-item CSD. Participants will rate each item using an 11-point scale ranging from 0 to 10 with higher scores indicating greater severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a ≥30 mm Reduction From Baseline in Cough Severity Visual Analog Scale (VAS) Score at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>To evaluate the efficacy of gefapixant based on improvement from Baseline in cough severity, assessed by the proportion of participants with a ≥30 mm reduction from baseline in Cough Severity VAS score at Week 24. The VAS is a single-item questionnaire with the response on a 100- point scale ranging from 0 (&quot;No Cough&quot;) to 100 (&quot;Extremely Severe Cough&quot;).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1290</enrollment>
  <condition>Chronic Cough</condition>
  <arm_group>
    <arm_group_label>Gefapixant 45 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a gefapixant 45 mg film-coated tablet BID during the main study period (24 weeks) and also during the extension period (28 weeks).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gefapixant 15 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a gefapixant 15 mg film-coated tablet BID during the main study period (24 weeks) and also during the extension period (28 weeks).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive a matching placebo tablet BID during the 24-week main study period and during the 28-week extension period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gefapixant 45 mg BID</intervention_name>
    <description>Gefapixant 45 mg (film-coated tablet) to be administered orally BID</description>
    <arm_group_label>Gefapixant 45 mg BID</arm_group_label>
    <other_name>MK-7264</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gefapixant 15 mg BID</intervention_name>
    <description>Gefapixant 15 mg (film-coated tablet) to be administered orally BID</description>
    <arm_group_label>Gefapixant 15 mg BID</arm_group_label>
    <other_name>MK-7264</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo tablet to be administered orally BID</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chest radiograph or computed tomography scan of the thorax (within 5 years of
             Screening/Visit 1 and after the onset of chronic cough) not demonstrating any
             abnormality considered to be significantly contributing to the chronic cough or any
             other clinically significant lung disease in the opinion of the principal investigator
             or the sub-investigator

          -  Has had chronic cough for at least 1 year with a diagnosis of refractory chronic cough
             or unexplained chronic cough

          -  Is a female who is not pregnant, not breastfeeding, not of childbearing potential, or
             agrees to follow contraceptive guidance

          -  Provides written informed consent and is willing and able to comply with the study
             protocol (including use of the digital cough recording device and completion of study
             questionnaires)

        Exclusion Criteria:

          -  Is a current smoker or has given up smoking within 12 months of Screening, or is a
             former smoker with greater than 20 pack-years

          -  Has a history of respiratory tract infection or recent clinically significant change
             in pulmonary status

          -  Has a history of chronic bronchitis

          -  Is currently taking an angiotensin converting enzyme inhibitor (ACEI), or has used an
             ACEI within 3 months of Screening

          -  Has a history of malignancy &lt;=5 years

          -  Is a user of recreational or illicit drugs or has had a recent history of drug or
             alcohol abuse or dependence

          -  Has a known allergy/sensitivity or contraindication to gefapixant

          -  Has donated or lost &gt;=1 unit of blood within 8 weeks prior to the first dose of
             gefapixant

          -  Has previously received gefapixant or is currently participating in or has
             participated in an interventional clinical study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Phoenix Medical Group ( Site 0022)</name>
      <address>
        <city>Peoria</city>
        <state>Arizona</state>
        <zip>85381</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>623-583-6542</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pulmonary Associates, PA ( Site 0063)</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>602-258-4951</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research Consortium ( Site 0088)</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>702-545-6766</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allergy &amp; Asthma Associates of SCV Research Center ( Site 0064)</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>408-553-0709</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lenus Research &amp; Medical Group Llc ( Site 0075)</name>
      <address>
        <city>Sweetwater</city>
        <state>Florida</state>
        <zip>33172</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>305-592-4692</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Atlanta Allergy &amp; Asthma Clinic PA ( Site 0029)</name>
      <address>
        <city>Stockbridge</city>
        <state>Georgia</state>
        <zip>30281</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>770-996-5354</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Healthcare Research Network LLC ( Site 0093)</name>
      <address>
        <city>Flossmoor</city>
        <state>Illinois</state>
        <zip>60422</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>708-388-2245</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Paul A. Shapero, MD ( Site 0104)</name>
      <address>
        <city>Bangor</city>
        <state>Maine</state>
        <zip>04401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>207-947-8658</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bethesda Allergy Asthma and Research Center LLC ( Site 0019)</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20814</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>301-907-3476</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Respiratory Medicine Research Institute of Michigan, PLC ( Site 0034)</name>
      <address>
        <city>Ypsilanti</city>
        <state>Michigan</state>
        <zip>48197</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>734-528-0477</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Minnesota Lung Center ( Site 0108)</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55435</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>952-852-5268</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Minnesota Lung Center ( Site 0041)</name>
      <address>
        <city>Woodbury</city>
        <state>Minnesota</state>
        <zip>55125</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>952-852-5268</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research Consortium ( Site 0050)</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>702-545-6840</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Atlantic Research Center LLC ( Site 0012)</name>
      <address>
        <city>Ocean City</city>
        <state>New Jersey</state>
        <zip>07712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>732-695-2555</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Albuquerque Clinical Trials ( Site 0039)</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>505-224-7407</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center ( Site 0098)</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>929-263-3262</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pulmonix LLC ( Site 0028)</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>336-323-5276</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wake Research Associates, LLC ( Site 0058)</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>919-781-2514</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Remington-Davis, Inc. ( Site 0082)</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>614-487-2560</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute of Southern Oregon, PC ( Site 0099)</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>541-494-3219</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allergy Associates Research Center ( Site 0026)</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>503-238-6233</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aapri Clinical Research Institute ( Site 0001)</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02886</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>401-681-4960</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lowcountry Lung &amp; Critical Care, PA ( Site 0045)</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>843-572-8545</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allergic Disease &amp; Asthma Center Research PA ( Site 0043)</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>8646273800221</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research of Rock Hill ( Site 0079)</name>
      <address>
        <city>Rock Hill</city>
        <state>South Carolina</state>
        <zip>29732</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>803-746-4542</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research Partners, LLC. ( Site 0080)</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>804-308-8659</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bellingham Asthma &amp; Allergy ( Site 0076)</name>
      <address>
        <city>Bellingham</city>
        <state>Washington</state>
        <zip>98225</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>360-733-5733</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Marycliff Clinical Research ( Site 0062)</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>509-343-3710</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Multicare Health System ( Site 0018)</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>253-403-0366</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Australian Clinical Research Network ( Site 0201)</name>
      <address>
        <city>Maroubra</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61293143400</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Western Respiratory Trials Specialists ( Site 0208)</name>
      <address>
        <city>Murdoch</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+610893121931</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Recherche GCP Research ( Site 0500)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H9H 4M7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>5148172307</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Q &amp; T Research Sherbrooke Inc. ( Site 0512)</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>H9H 4M7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8195626374</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique de Pneumologie et du Sommeil de Lanaudiere- CPSL ( Site 0516)</name>
      <address>
        <city>St-Charles-Borromee</city>
        <state>Quebec</state>
        <zip>H9H 4M7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4507555491</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CIC Mauricie Inc. ( Site 0503)</name>
      <address>
        <city>Trois-Rivieres</city>
        <state>Quebec</state>
        <zip>H9H 4M7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8193731128</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Herlev Hospital ( Site 0803)</name>
      <address>
        <city>Herlev</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4538683297</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aerztezentrum Axel Springer Passage ( Site 1009)</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4930259393817</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Zentrum ( Site 1005)</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+496915053976</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pneumologicum im Suedstadtforum ( Site 1004)</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+495111691755</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ballenberger. Freytag. Wenisch - Institut fuer klinische Forschung GmbH ( Site 1011)</name>
      <address>
        <city>Neu-Isenburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+496102809710</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>PneumoConsult Ulm ( Site 1008)</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+491727927484</phone>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 22, 2018</study_first_submitted>
  <study_first_submitted_qc>February 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2018</study_first_posted>
  <last_update_submitted>May 24, 2018</last_update_submitted>
  <last_update_submitted_qc>May 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cough</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

